Cargando…
Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States
INTRODUCTION: The treatment of multiple myeloma (MM) remains a challenge as patients eventually progress through several lines of therapy (LOTs), requiring use of multiple MM drug classes. In this retrospective US claims-database study, we examined the healthcare costs of patients with MM who receiv...
Autores principales: | Jagannath, Sundar, Joseph, Nedra, He, Jinghua, Crivera, Concetta, Fu, Alex Z., Garrett, Ashraf, Shah, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681939/ https://www.ncbi.nlm.nih.gov/pubmed/35579821 http://dx.doi.org/10.1007/s40487-022-00198-0 |
Ejemplares similares
-
Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US
por: Jagannath, Sundar, et al.
Publicado: (2021) -
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
por: Jagannath, Sundar, et al.
Publicado: (2023) -
Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2020) -
P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
por: Manier, Salomon, et al.
Publicado: (2023) -
Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008
por: Jagannath, Sundar
Publicado: (2009)